Modality
Multispecific
MOA
Menini
Target
CGRP
Pathway
Checkpoint
Crohn's
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
Apr 2019
→ Jul 2026
Phase 1Current
NCT07899390
454 pts·Crohn's
2019-04→2025-10·Terminated
NCT06698164
1,541 pts·Crohn's
2023-09→2026-07·Terminated
1,995 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-265mo agoInterim· Crohn's
2026-07-234mo awayInterim· Crohn's
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Termina…
P1
Termina…
Catalysts
Interim
2025-10-26 · 5mo ago
Crohn's
Interim
2026-07-23 · 4mo away
Crohn's
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07899390 | Phase 1 | Crohn's | Terminated | 454 | VA |
| NCT06698164 | Phase 1 | Crohn's | Terminated | 1541 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |